In his weekly clinical update, Dr. Griffin discusses the CDC HIV surveillance report, FDA voted in favor of approving the Abrysvo vaccine, canine olfactory detection of SARS-CoV-2-infected humans, safety of the BNT162b2 COVID-19 vaccine in children aged 5 to 17 years, and statement on the antigen composition of COVID-19 vaccines.
Click arrow to play Download TWiV 1010 (21 MB .mp3, 36 min)
Vincent travels to Montreux, Switzerland and the 16th International Nidovirus Symposium, where he speaks with Maria von Kerkhove, the face of COVID-19 for the World Health Organization, and Kanta Subbarao, Director of the WHO Collaborating Centre on Influenza in Melbourne.
In his weekly clinical update, Dr. Griffin discusses variant specific clinical performance of a SARS-CoV-2 rapid antigen test with focus on omicron VOC, ventilation in buildings, COVID-19 mortality among selective serotonin reuptake inhibitor users, risk of post-acute sequelae of SARS-CoV-2 infection associated with pre-coronavirus disease obstructive sleep apnea diagnoses, trajectories of the evolution of post COVID-19 condition, and efficacy of cognitive behavioral therapy targeting severe fatigue following COVID-19.
Click arrow to play Download TWiV 1008 (19 MB .mp3, 32 min)
TWiV explains genetic changes in nOPV2 strains that paralyzed children, outbreak of raccoon distemper in Toronto, EcoHealth Alliance gets its NIH grant back, and breakage at chromosomal fragile sites caused by the EBNA1 protein of Epstein-Barr virus as a mechanism for carcinogenesis.
In his weekly clinical update, Dr. Griffin discusses immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age, influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults, COVID-19 surveillance after expiration of the public health emergency declaration, provisional mortality data, targeted vaccine messaging to promote COVID-19 vaccines for children and youth, vaccines and related biological products advisory committee meeting June 15, 2023 announcement, how to overhaul the CDC, impact of SARS-CoV-2 variants on inpatient clinical outcome, prevalence of post-coronavirus disease condition 12 weeks after Omicron infection compared with negative controls and association with vaccination status, gut bacteria cocktail helps long COVID, and gut microbiota‐derived symbiotic formula (SIM01) as a novel adjuvant therapy for COVID‐19.
Click arrow to play Download TWiV 1006 (26 MB .mp3, 43 min)
TWiV reveals plankton-infecting relatives of herpesviruses in the sunlit oceans, and a vaccine encoding non-spike T cell antigens that protects animals from severe SARS-CoV-2 infection.
In his weekly clinical update, Dr. Griffin discusses the U.S. Food and Drug Administration approving Arexvy: the first respiratory syncytial virus (RSV) vaccine approved for use in the United State, association between SARS-CoV-2 and metagenomic content of samples from the Huanan Seafood Market, researchers disagree over how bad it is to be reinfected and whether COVID-19 can cause lasting changes to the immune system, virtual care and emergency department use during the COVID-19 pandemic among patients of family physicians in Canada, vaccination with BCG-Denmark did not result in a lower risk of COVID-19 among health care workers than placebo, NVX-CoV2373 vaccine efficacy against hospitalization, comparative effectiveness of the SARS-COV-2 vaccines during Delta dominance, assessment of gender-specific COVID-19 case fatality risk per malignant neoplasm type, clinical outcomes following treatment for COVID-19 with Nirmatrelvir/Ritonavir and Molnupiravir among patients living in nursing homes, timing of intubation and ICU mortality in COVID-19 patients, real-life experience with Remdesivir for treatment of COVID-19 among older adults, and how long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection.
Click arrow to play Download TWiV 1004 (32 MB .mp3, 53 min)
Vincent and Kathy travel to Atlanta for APHL ID Lab Con, a conference focused on the latest developments in detection and characterization of infectious diseases of public health concern, and speak with Megan, Ryan, and Kirsten about the workings of public health and clinical laboratories.
In his weekly clinical update, Dr. Griffin discusses completeness and spin of medRxiv preprints and associated published abstracts of COVID-19 randomized clinical trials, lessons learned from a COVID-19 dog screening pilot in California K-12 schools, SARS-CoV-2 reinfection and severity of the disease, effectiveness of COVID-19 bivalent vaccine, Molnupiravir and risk of post-acute sequelae of COVID-19, risk of new-onset long Covid following reinfection with SARS-CoV-2, low vitamin D levels associated with long COVID syndrome in COVID-19 survivors, and clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”.
Click arrow to play Download TWiV 1002 (27 MB .mp3, 44 min)
In his weekly clinical update, Dr. Griffin discusses an update on vaccine-derived poliovirus outbreaks, how the dream of wiping out polio might need a rethink, risk of death in patients hospitalized for COVID-19 vs seasonal Influenza in fall-winter, French Mpox cluster includes fully vaccinated patients, two individuals with potential Mpox virus reinfection, epidemiologic and clinical features of Mpox-associated deaths, FDA authorizes changes to simplify use of bivalent mRNA COVID-19 vaccines, SARS-CoV-2 during Omicron variant predominance among infants born to people with SARS-CoV-2, severe maternal morbidity and mortality of pregnant patients with COVID-19 infection during the early pandemic period in the US, sickness presenteeism in healthcare workers during the COVID-19 pandemic, ventilation improvements among k–12 public school districts, risk factors and vectors for SARS-CoV-2 household transmission, SARS-CoV-2 neutralizing antibodies after bivalent versus monovalent, durability of bivalent boosters against Omicron subvariants, Nirmatrelvir and risk of hospital admission or death in adults with COVID-19, evolving real-world effectiveness of monoclonal antibodies for treatment of COVID-19, effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support–free days in patients hospitalized with COVID-19, efficacy and safety of Anakinra plus standard of care for patients with severe COVID-19, higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support, risk of autoimmune diseases in patients with COVID-19, definition of post–COVID-19 condition among published research studies, and sleep disturbance severity and correlates in post-acute sequelae of COVID-19.
Click arrow to play Download TWiV 1001 (26 MB .mp3, 43 min)
Your donations help make our podcasts happen. Support our work at Patreon, PayPal, and more. MicrobeTV, Inc. is a 501(c)3 non-profit organization.
Donate Now
Questions/Comments
Do you have any thoughts on or questions about our podcast episodes? Send them to us at twiv@microbe.tv!
